The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Radioembolization for Hepatocellular Carcinoma-Current Evidence and Patterns of Utilization
J Vasc Interv Radiol. 2023 Mar 29;S1051-0443(23)00254-3.doi: 10.1016/j.jvir.2023.03.020. Online ahead of print.
10Interventional Radiology Service, Department of Radiology, Northern Health, Melbourne, Australia; Interventional Radiology Service, St Vincent's Hospital, Melbourne, Australia. Electronic address: terry.kok@nh.org.au.
Abstract
Primary liver malignancy, of which hepatocellular carcinoma (HCC) is the most common type, is the second most common cause of death due to cancer worldwide. Given the historically poor prognosis of liver cancer, there has been major research on its treatment options, with significant advancements over the last decade. Transarterial radioembolization (TARE) is a locoregional treatment option for HCC that involves transarterial delivery of the β-emitter yttrium-90 via resin or glass microspheres to arterialized tumor vasculature, delivering a tumoricidal dose to the tumor. The recent 2022 update of the Barcelona Clinic Liver Cancer (BCLC) treatment algorithm has featured a more prominent role of locoregional treatment, including the incorporation of radioembolization for very-early-stage (BCLC 0) and early-stage (BCLC A) diseases. This review provides a contemporary summary of the evolving role of TARE in HCC treatment in light of recent and upcoming trials.